OLIG2 inhibition by either genetic deficiency or pharmacological targeting with CT-179 sensitized GBM tumors to anti-PD-L1 therapy, enhancing antitumor immune responses and prolonging survival. This evidence concerns the gene OLIG2 and glioblastoma.